PSMA-PET在未达Phoenix生化复发标准的前列腺癌放疗后患者中检测复发
该亚组中53例(84.1%)仍检出PSMA-PET阳性病灶,21例(33.3%)为局部单发复发,32例(50.8%)存在转移。除PSA升高外未发现其他预测早期PSMA-PET的因子。
要点
- 放疗后PSA升高未达Phoenix标准时,PSMA-PET仍可高频检出复发灶。
- 该亚组中84.1%检出PSMA-PET阳性病灶,50.8%为转移性前列腺癌。
- 除PSA升高外,无其他因素可预测需早期行PSMA-PET。
核心结论
- 在放疗后PSA升高但未达Phoenix生化复发标准的患者中,PSMA-PET常可检出转移性前列腺癌。
- 研究结果提示需重新评估放疗后PSA升高的现行诊断流程。
研究设计与样本
- 回顾性队列研究,纳入Prostate Cancer Network Amsterdam(2015-2018)中根治性放疗后行PSMA-PET的315例前列腺癌患者。
主要发现
- 21例(33.3%)为局部复发且为单一病灶,32例(50.8%)存在转移性前列腺癌。
- 除PSA升高外,未发现其他促使早期行PSMA-PET的预测因素。
关键数值与推荐
- Phoenix标准(2005)定义生化复发为PSA较最低值升高≥2 ng/ml。
- 本研究中未达Phoenix标准指PSA升高<2.0 ng/ml。
临床怎么用
- 放疗后PSA升高但未达Phoenix标准时,可考虑行PSMA-PET以早期发现复发。
- 早期检出复发可能有助于优化挽救性和/或辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biochemical recurrence of prostate cancer (PCa) after curative radiotherapy is defined as a prostate-specific antigen (PSA) rise of ≥2 ng/ml above the nadir ("Phoenix criteria", 2005). With the introduction of prostate-specific membrane antigen positron emission tomography (PSMA-PET), the ability to localise PCa recurrences has increased markedly. Here, we reviewed 315 patients scanned with PSMA-PET after curative radiotherapy in the Prostate Cancer Network Amsterdam (2015-2018). Sixty-three patients (20.3%) were scanned below the Phoenix threshold (PSA rise <2.0 ng/ml). In 53 of these patients (84.1%), PSMA-PET-avid lesions were detected nonetheless: 21 patients (33.3%) revealed a local recurrence as a single site of disease, 32 patients (50.8%) harboured metastatic PCa. Besides rising PSA, no predictors were identified that prompted early PSMA-PET imaging. In this communication, we report on the frequent detection of metastatic PCa with PSMA-PET in men below the Phoenix PSA threshold. These findings are a plea for re-evaluation of current diagnostic work-up for rising PSA values after radiotherapy, as early detection of recurrences might refine salvage and/or adjuvant therapies. PATIENT SUMMARY: This study reports on the unexpected detection of prostate cancer (PCa) recurrences with prostate-specific membrane antigen positron emission tomography in patients treated with radiotherapy. This calls for re-evaluation of the current criteria for recurrent PCa after radiotherapy.
引用
- Jansen BHE, van Leeuwen PJ, Wondergem M, et al. Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. Eur Urol Oncol. 2020. PMID: 32088155. doi:10.1016/j.euo.2020.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。